NEW YORK, Oct. 19 - Invitrogen has been granted a non-exclusive sub-license from Gryphon Sciences to use its Native Chemical Ligation patent, which allow researchers to synthesize proteins using chemical, rather than biological means, Gryphon said on Friday.

The patent, numbered 6,184,344 and entitled "Synthesis of Proteins by Native Chemical Ligation," covers processes for making proteins that retain the biologic activity of the native molecule and can have specific functionality built into them, according to Gryphon. 

Financials terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.